Fresh from the biologic pipeline-2009

Nature Biotechnology

Volumn 28, Issue 4, 2010, Pages 307-310

  Sheridan, Cormac ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ARZERRA; CANAKINUMAB; DENOSUMAB; INFLIXIMAB; KALBITOR; MONOCLONAL ANTIBODY; PANITUMUMAB; RACHELMYCIN; RECOMBINANT ANTITHROMBIN III; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REMOVAB; RITUXIMAB; SAXAGLIPTIN; SIMPONI; TOCILIZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; USTEKINUMAB;

ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; ANTITHROMBIN DEFICIENCY; ASCITES TUMOR; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY CARCINOMA; NONHODGKIN LYMPHOMA; NOTE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; DRUG APPROVAL; DRUG INDUSTRY; UNITED STATES;

EID: 77950666079     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0410-307     Document Type: Note

References (6)

1. http://www.landesbioscience.com/journals/mabs/about#background
2. Anonymous. CDer new Molecular entity (nMe)/new BLA Calendar Year Approvals As of December 31 2009 (FDA CDer, washington, DC, 2009).
3. http://www.fda. gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/DrugandBiologicApprovalreports/ nMeDrugandnewBiologicApprovals/uCM091096.
4. Hughes, B. Nat. Rev. Drug Disc. 9, 89-92 (2010).
5. Segal, B.M. et al. Lancet Neurol. 7, 796-804 (2008).
6. Pappas, D.A. et al. Nat. Rev. Drug Disc. 8, 695-696 (2009).